Abstract
This post hoc analysis of the XIRIUS and XOLARIS studies investigates how changes in visual function associated with cotoretigene toliparvovec gene therapy in participants with
RPGR
-variant X-linked retinitis pigmentosa compare with those of untreated individuals.